30.89

0.68% 0.21

Pre-market: 30.86 -0.03 -0.10%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Financials Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is traded at $30.89, with a volume of 1.22M. It is up +0.68% in the last 24 hours and down -9.81% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Previous Close:

$30.68

Open:

$30.58

24h Volume:

1.22M

Relative Volume:

0.53

Market Cap:

$3.59B

Revenue:

Net Income/Loss:

$-472.34M

P/E Ratio:

-7.4507

EPS:

-4.1459

Net Cash Flow:

$-340.33M

1W Performance:

+2.05%

1M Performance:

-9.81%

6M Performance:

-9.84%

1Y Performance:

+11.40%

1-Day Range:

$30.29

$30.92

1-Week Range:

$28.16

$30.92

52-Week Range:

$22.96

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

858-704-4660

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2026-04-29

Latest SEC Filings

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VKTX Viking Therapeutics Inc	30.89	3.56B	0	-472.34M	-340.33M	-4.1459
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Oct-29-25	Initiated	Canaccord Genuity	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Goldman	Neutral
Feb-13-25	Initiated	Scotiabank	Sector Outperform
Feb-07-25	Initiated	Citigroup	Neutral
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy
Nov-04-24	Reiterated	H.C. Wainwright	Buy
Sep-11-24	Initiated	JP Morgan	Overweight
Jun-27-24	Initiated	Morgan Stanley	Overweight
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-26-24	Reiterated	Oppenheimer	Outperform
Mar-07-24	Initiated	Jefferies	Buy
Feb-28-24	Reiterated	Oppenheimer	Outperform
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

04:44 AM

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - AOL.com

04:44 AM

04:18 AM

Is Viking Therapeutics (VKTX) Pricing In Too Much Optimism After Recent Share Price Swings? - simplywall.st

04:18 AM

04:04 AM

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - The Motley Fool

04:04 AM

May 25, 2026

Don't Buy Viking Therapeutics Stock Until You Read This - AOL.com

May 25, 2026

A Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent Returns - Yahoo Finance

May 25, 2026

May 23, 2026

Is Viking Therapeutics a Top Takeover Target? - The Motley Fool

May 23, 2026

Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors? - simplywall.st

May 23, 2026

Viking Therapeutics, Inc. Stock 12‑Month Price Target Raised to $95.4, Implies 209% Upside - TradingView

May 23, 2026

May 22, 2026

Viking Therapeutics Analyst Ratings and Price Targets | NASDAQ:VKTX - Benzinga

May 22, 2026

2 Stocks That Could Realistically Double by 2030 - The Motley Fool

May 22, 2026

VKTX Technical Analysis | Trend, Signals & Chart Patterns | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill

May 22, 2026

May 21, 2026

Viking Therapeutics faces timeline risk, but upside could be huge - MSN

May 21, 2026

Could Viking Therapeutics Be the Next Eli Lilly? - The Motley Fool

May 21, 2026

Viking Therapeutics to Participate at Upcoming Investor Conferences - PR Newswire

May 21, 2026

May 18, 2026

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Globe and Mail

May 18, 2026

Three Biotechs That Are Top Takeover Targets - 24/7 Wall St.

May 18, 2026

Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal

May 18, 2026

May 17, 2026

VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests - MSN

May 17, 2026